Skip To Voice Support Menu
For Body
For Menu
For Local Menu
Site Map
Text Size
Normal
Home
About Chugai
Group Companies
Patients
Research and Development
Careers
Contact
Chugai Pharma USA, LLC is now Chugai Pharma USA, Inc
Aug 11, 2015 Caution Regarding False Solicitations on Behalf of Chugai
May 14, 2015 Warning against Phishing e-mails and social networking sites using the name of Chugai Pharmaceutical
News Releases
What's New
06 Dec
“Let’s Learn about Cancer Genomic Medicine,” Chugai’s Website for Patients and the General Public, Won the Asakawa Award in the 7th Web GRAND PRIX
04 Dec
R&I Raises Chugai's Issuer Rating from “AA –” to “AA”
02 Dec
Chugai Completes Transfer of Rights to Maruho for Oxarol® Ointment 25µg/g and Oxarol® Lotion 25µg/g, Therapeutic Agents for Keratosis including Psoriasis Vulgaris, and Marduox® Ointment, a Therapeutic Agent for Psoriasis Vulgaris
29 Nov
Results from Phase III SAkuraSky Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in The New England Journal of Medicine Online
27 Nov
Chugai Launches Tecentriq Intravenous Infusion 840 mg as an Optimal Formulation for the Treatment of PD-L1-Positive Inoperable or Metastatic Triple Negative Breast Cancer
More
Video Introduction of CHUGAI
Videos & Advertisements
Share this site